Kalvista Pharmaceuticals Inc
KALV15.170USD
-0.620-3.93%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
766.73MMarket Cap
LossP/E TTM
More Details of Kalvista Pharmaceuticals Inc Company
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
Kalvista Pharmaceuticals Inc Info
Ticker SymbolKALV
Company nameKalvista Pharmaceuticals Inc
IPO dateApr 09, 2015
CEOPalleiko (Benjamin L)
Number of employees270
Security typeOrdinary Share
Fiscal year-endApr 09
Address200 Crossing Boulevard
CityFRAMINGHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01702
Phone18579990075
Websitehttps://www.kalvista.com/
Ticker SymbolKALV
IPO dateApr 09, 2015
CEOPalleiko (Benjamin L)
Company Executives of Kalvista Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Benjamin L. (Ben) Palleiko
Mr. Benjamin L. (Ben) Palleiko
Chief Executive Officer, Director
Chief Executive Officer, Director
424.52K
+2.00%
Dr. Christopher M. Yea, Ph.D.
Dr. Christopher M. Yea, Ph.D.
Chief Development Officer
Chief Development Officer
223.51K
+69.26%
Dr. Paul K. Audhya, M.D.
Dr. Paul K. Audhya, M.D.
Chief Medical Officer
Chief Medical Officer
131.83K
+7.61%
Ms. Nicole Sweeny
Ms. Nicole Sweeny
Chief Commercial Officer
Chief Commercial Officer
15.34K
+94.07%
Mr. Brian Piekos
Mr. Brian Piekos
Chief Financial Officer
Chief Financial Officer
10.53K
--
Ms. Linea Aspesi
Ms. Linea Aspesi
Chief People Officer
Chief People Officer
--
--
Mr. Bilal Arif
Mr. Bilal Arif
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Mr. Edward W. Unkart, CPA
Mr. Edward W. Unkart, CPA
Independent Director
Independent Director
--
--
Mr. Laurence E. Reid, Ph.D.
Mr. Laurence E. Reid, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Benjamin L. (Ben) Palleiko
Mr. Benjamin L. (Ben) Palleiko
Chief Executive Officer, Director
Chief Executive Officer, Director
424.52K
+2.00%
Dr. Christopher M. Yea, Ph.D.
Dr. Christopher M. Yea, Ph.D.
Chief Development Officer
Chief Development Officer
223.51K
+69.26%
Dr. Paul K. Audhya, M.D.
Dr. Paul K. Audhya, M.D.
Chief Medical Officer
Chief Medical Officer
131.83K
+7.61%
Ms. Nicole Sweeny
Ms. Nicole Sweeny
Chief Commercial Officer
Chief Commercial Officer
15.34K
+94.07%
Mr. Brian Piekos
Mr. Brian Piekos
Chief Financial Officer
Chief Financial Officer
10.53K
--
Ms. Linea Aspesi
Ms. Linea Aspesi
Chief People Officer
Chief People Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
VR Adviser, LLC
13.31%
Tang Capital Management, LLC
9.97%
Frazier Life Sciences Management, L.P.
9.94%
Suvretta Capital Management, LLC
9.43%
Capital World Investors
6.29%
Other
51.06%
Shareholders
Shareholders
Proportion
VR Adviser, LLC
13.31%
Tang Capital Management, LLC
9.97%
Frazier Life Sciences Management, L.P.
9.94%
Suvretta Capital Management, LLC
9.43%
Capital World Investors
6.29%
Other
51.06%
Shareholder Types
Shareholders
Proportion
Hedge Fund
43.98%
Investment Advisor
34.67%
Investment Advisor/Hedge Fund
14.06%
Venture Capital
13.31%
Private Equity
9.94%
Research Firm
6.18%
Individual Investor
1.74%
Pension Fund
0.26%
Sovereign Wealth Fund
0.26%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
304
58.90M
116.58%
-6.90M
2025Q2
293
60.52M
121.15%
-6.23M
2025Q1
300
56.85M
114.35%
-10.03M
2024Q4
295
57.02M
115.39%
-4.36M
2024Q3
292
50.23M
115.93%
-11.73M
2024Q2
292
49.87M
116.71%
-8.51M
2024Q1
293
49.24M
116.93%
-4.79M
2023Q4
269
38.06M
110.17%
-12.86M
2023Q3
274
38.57M
113.73%
-12.48M
2023Q2
275
36.74M
108.90%
-12.50M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
VR Adviser, LLC
6.73M
13.32%
--
--
Jun 30, 2025
Tang Capital Management, LLC
4.94M
9.78%
--
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
4.89M
9.67%
--
--
Aug 18, 2025
Suvretta Capital Management, LLC
4.96M
9.81%
+41.99K
+0.85%
Jun 30, 2025
Capital World Investors
3.18M
6.29%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.76M
5.45%
-78.63K
-2.77%
Jun 30, 2025
The Vanguard Group, Inc.
2.41M
4.77%
+113.80K
+4.95%
Jun 30, 2025
Emerald Advisers LLC
1.81M
3.58%
+300.62K
+19.96%
Jun 30, 2025
Medical Strategy GmbH
1.55M
3.07%
+800.79K
+107.06%
Jul 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.56%
Invesco NASDAQ Future Gen 200 ETF
0.43%
State Street SPDR S&P Biotech ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Micro-Cap ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.04%
Fidelity Enhanced Small Cap ETF
0.04%
Vanguard US Momentum Factor ETF
0.02%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.56%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.43%
State Street SPDR S&P Biotech ETF
Proportion0.15%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.09%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.04%
Fidelity Enhanced Small Cap ETF
Proportion0.04%
Vanguard US Momentum Factor ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Kalvista Pharmaceuticals Inc?
The top five shareholders of Kalvista Pharmaceuticals Inc are:
VR Adviser, LLC holds 6.73M shares, accounting for 13.32% of the total shares.
Tang Capital Management, LLC holds 4.94M shares, accounting for 9.78% of the total shares.
Frazier Life Sciences Management, L.P. holds 4.89M shares, accounting for 9.67% of the total shares.
Suvretta Capital Management, LLC holds 4.96M shares, accounting for 9.81% of the total shares.
Capital World Investors holds 3.18M shares, accounting for 6.29% of the total shares.
VR Adviser, LLC holds 6.73M shares, accounting for 13.32% of the total shares.
Tang Capital Management, LLC holds 4.94M shares, accounting for 9.78% of the total shares.
Frazier Life Sciences Management, L.P. holds 4.89M shares, accounting for 9.67% of the total shares.
Suvretta Capital Management, LLC holds 4.96M shares, accounting for 9.81% of the total shares.
Capital World Investors holds 3.18M shares, accounting for 6.29% of the total shares.
What are the top three shareholder types of Kalvista Pharmaceuticals Inc?
The top three shareholder types of Kalvista Pharmaceuticals Inc are:
VR Adviser, LLC
Tang Capital Management, LLC
Frazier Life Sciences Management, L.P.
VR Adviser, LLC
Tang Capital Management, LLC
Frazier Life Sciences Management, L.P.
How many institutions hold shares of Kalvista Pharmaceuticals Inc (KALV)?
As of 2025Q3, 304 institutions hold shares of Kalvista Pharmaceuticals Inc, with a combined market value of approximately 58.90M, accounting for 116.58% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -4.57%.
What is the biggest source of revenue for Kalvista Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Kalvista Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
